Intergroupe Francophone De Cancerologie Thoracique

This study is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps older adults (aged 70-89) with advanced non-small cell lung cancer live longer. It aims to see if this combination is as effective and safe for this older age group as it has b…

This study is testing whether the drug lorlatinib can help control advanced lung cancer with a specific genetic change (ROS1-positive) after the first targeted treatment has stopped working. It will involve about 54 adults whose cancer has continued to grow despite prior therapy.…

This study is for people with advanced non-small cell lung cancer that has continued to grow despite receiving both chemotherapy and immunotherapy. Researchers want to see if adding a drug called atezolizumab to a standard two-drug combination (paclitaxel and bevacizumab) can hel…

This study is testing if a targeted drug called brigatinib works better alone or when combined with two chemotherapy drugs for people with advanced lung cancer that has a specific genetic change (ALK-positive). About 110 patients who haven't had treatment for their advanced cance…

This study is testing whether a combination of two targeted drugs, encorafenib and binimetinib, can help control advanced non-small cell lung cancer that has a specific genetic change called BRAF V600E. It is for adults whose cancer has spread and who have either had no prior tre…

This study is testing a new first-line treatment for extensive-stage small cell lung cancer. It combines a different chemotherapy (paclitaxel and carboplatin) with an immunotherapy drug (durvalumab) to see if it works better than the current standard treatment. The main goal is t…